US · A
Agilent Technologies, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Santa Clara, CA 95051
- Website
- agilent.com
Price · as of 2025-10-31
$114.52
Market cap 34.41B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $96.06 | -16.12% |
| Intrinsic Value(DCF) | $63.13 | -44.87% |
| Graham-Dodd Method(GD) | $16.09 | -85.95% |
| Graham Formula(GF) | $67.38 | -41.16% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $23.73 | $71.95 | $46.59 | $22.48 | $83.97 |
| 2012 | $27.83 | $54.92 | $83.07 | $18.28 | $38.35 |
| 2013 | $38.15 | $54.21 | $5.36 | $10.32 | $0.00 |
| 2014 | $37.08 | $50.69 | $2.56 | $8.71 | $19.71 |
| 2015 | $35.63 | $45.25 | $1.51 | $5.40 | $9.56 |
| 2016 | $44.79 | $52.20 | $5.98 | $5.44 | $16.87 |
| 2017 | $65.83 | $61.13 | $7.90 | $9.59 | $30.27 |
| 2018 | $66.90 | $62.88 | $6.93 | $0.96 | $17.23 |
| 2019 | $83.97 | $66.25 | $5.99 | $10.89 | $44.04 |
| 2020 | $122.60 | $80.91 | $2.18 | $4.97 | $26.49 |
| 2021 | $140.85 | $99.82 | $38.83 | $12.91 | $102.41 |
| 2022 | $144.43 | $100.52 | $38.29 | $12.95 | $67.80 |
| 2023 | $128.62 | $97.23 | $12.58 | $13.98 | $33.48 |
| 2024 | $136.37 | $99.88 | $6.04 | $12.96 | $15.73 |
| 2025 | $148.26 | $96.06 | $8.01 | $16.09 | $67.38 |
AI valuation
Our deep-learning model estimates Agilent Technologies, Inc.'s (A) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $96.06
- Current price
- $114.52
- AI upside
- -16.12%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$63.13
-44.87% upside
Graham-Dodd
$16.09
-85.95% upside
Graham Formula
$67.38
-41.16% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| A | Agilent Technologies, Inc… | $114.52 | 34.41B | -16% | -45% | -86% | -41% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $87.18 | 42.49B | -32% | -61% | -65% | -71% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| EW | Edwards Lifesciences Corp… | $86.47 | 50.77B | -6% | -55% | -72% | -59% | 47.67 | 4.93 | 8.40 | 33.68 | — | 6.85 | 78.13% | 26.97% | 17.69% | 10.52% | 19.08% | 7.99% | 0.01 | — | 3.72 | 2.12 | -1.98 | -7374.00% | 1155.00% | 36050.00% | 2.62% | 0.88 | 18.76% | 0.00% | 0.00% | 2.71% | 29.43 | 36.07 | 7.94 | 11.83 |
| HLN | Haleon plc | $11.07 | 49.3B | +256% | -54% | — | -81% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| INSM | Insmed Incorporated | $149.33 | 31.85B | -50% | +3,425% | — | — | -24.48 | 42.30 | 51.55 | -26.12 | -162.35 | 61.87 | 79.41% | -194.04% | -210.54% | -249.28% | -969.45% | -59.53% | 1.04 | -14.04 | 3.83 | 3.35 | -0.22 | 1508.00% | 6673.00% | 3709.00% | -3.10% | -1.99 | -797.14% | 0.00% | 0.00% | 1.60% | -26.00 | -31.62 | 50.46 | 8.06 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| MTD | Mettler-Toledo Internatio… | $1,366.69 | 27.92B | -28% | -53% | -87% | -63% | 31.42 | -1155.46 | 6.78 | 23.96 | 851.91 | -26.22 | 57.52% | 27.78% | 21.59% | -1154.87% | 44.16% | 25.00% | -99.14 | 16.32 | 1.14 | 0.71 | 1.84 | 369.00% | 398.00% | -183.00% | 3.11% | 0.80 | 40.43% | 0.00% | 0.00% | 2.93% | 26.45 | 34.86 | 7.35 | 10.00 |
| RMD | ResMed Inc. | $256.26 | 37.41B | -10% | -40% | -86% | -35% | 28.88 | 6.78 | 7.86 | 20.96 | 77.17 | 16.47 | 59.36% | 32.75% | 27.22% | 25.86% | 25.33% | 18.62% | 0.14 | 133.66 | 3.44 | 2.16 | -0.19 | 3743.00% | 984.00% | 2918.00% | 4.11% | 1.72 | 29.91% | 0.77% | 22.20% | 3.96% | 23.79 | 24.13 | 7.79 | 13.72 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
About Agilent Technologies, Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
- CEO
- Padraig McDonnell
- Employees
- 17.9K
- Beta
- 1.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($63.13 ÷ $114.52) − 1 = -44.87% (DCF, example).